- Home
- ASND vs PODD Comparison
ASND vs PODD Comparison
Compare ASND & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ASND | PODD |
|---|---|---|
| Founded | 2006 | 2000 |
| Country | Denmark | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.7B | 17.0B |
| IPO Year | 2014 | 2007 |
Fundamental Metrics
Financial Performance| Metric | ASND | PODD |
|---|---|---|
| Price | $228.78 | $188.78 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 16 | 20 |
| Target Price | $281.50 | ★ $347.55 |
| AVG Volume (30 Days) | 605.2K | ★ 772.6K |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 3.48 |
| Revenue | N/A | ★ $2,708,100,000.00 |
| Revenue This Year | $96.35 | $24.55 |
| Revenue Next Year | $44.91 | $19.18 |
| P/E Ratio | ★ N/A | $54.94 |
| Revenue Growth | N/A | ★ 30.73 |
| 52 Week Low | $151.11 | $189.63 |
| 52 Week High | $250.74 | $354.88 |
Technical Indicators
Market Signals| Indicator | ASND | PODD |
|---|---|---|
| Relative Strength Index (RSI) | 45.98 | 25.60 |
| Support Level | $214.92 | N/A |
| Resistance Level | $236.58 | $205.95 |
| Average True Range (ATR) | 8.63 | 5.41 |
| MACD | -1.45 | 0.19 |
| Stochastic Oscillator | 35.81 | 11.12 |
Price Performance
Historical ComparisonAbout ASND Ascendis Pharma A/S
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.
About PODD Insulet Corporation
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.